Live Markets
Saturday, September 12, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Jyong Biotech Ltd. (MENS)

NGM · Biotechnology

$1.99-0.02 (-1.00%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$151.3M
P/E (TTM)
EPS
$-0.06
Div Yield
52W Range
$1.43–$67.00
Beta

Company overview

Next earnings: 2026-11-12(62d)

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Peers in Biotechnology

All in industry →

Recent press releases

Jyong Biotech Ltd. has not issued a press release in this window.

SEC filings

All filings →

Jyong Biotech Ltd. has not filed an SEC document in this window.

Jyong Biotech Ltd. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
64,382 sh+19.6%
260,823 sh● NEW
UBS Group AG$575,310
145,648 sh+27022.5%
40,258 sh+209.4%
69,560 sh● NEW
23,182 sh● NEW
1,300 sh-23.4%
14,222 sh● NEW

People at Jyong Biotech Ltd.

All people →

No officers or directors have been indexed for Jyong Biotech Ltd..

Quarterly financials

Full financials →

No quarterly financials have been ingested for Jyong Biotech Ltd..

Jyong Biotech Ltd. (MENS) Stock Quote, Press... | Cayman Journal | Cayman Journal